Covishield – Serum International Institute
Indication and Usage –
- COVISHIELD is indicated for active immunisation of individuals ≥18 years old for the prevention of coronavirus disease 2019 (COVID-19).
Dosage and Administration –
- COVISHIELD vaccination course consists of two separate doses of 0.5 ml each. The second dose should be administered between 4 to 12 weeks after the first dose.
- It is recommended that individuals who receive a first dose of COVISHIELD complete the vaccination course with COVISHIELD.
- COVISHIELD is for intramuscular (IM) injection only, preferably in the deltoid muscle
Contraindications –
- Hypersensitivity to the active substance or to any of the excipient L-Histidine, L-Histidine hydrochloride monohydrate, Magnesium chloride hexahydrate, Polysorbate 80, Ethanol, Sucrose, Sodium chloride, Disodium edetate dihydrate (EDTA).
- Patients who have experienced major venous and/or arterial thrombosis in combination with thrombocytopenia following vaccination with any COVID-19 vaccine should not receive a second dose of ChAdOx1 nCoV- 19 Corona Virus Vaccine (Recombinant).
Adverse reactions –
- Some recipients have reported chills, shivering (in some cases rigors), and increased body temperature possibly with sweating, headache (including migraine-like headaches), nausea, myalgia and malaise, starting within a day of vaccination. These effects usually last for a day or two.
- If a patient reports unusually high or prolonged fever, or other symptoms, alternative causes should be considered and appropriate advice should be provided for diagnostic investigation and medical management as required.
Drug interactions and other interactions –
- No interaction studies have been performed. Concomitant administration of Covishield with other vaccines has not been studied.
